TARKA

This brand name is authorized in United States. It is also authorized in Australia, Croatia, Ecuador, Estonia, France, Germany, Lithuania, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Turkey.

Active ingredients

The drug TARKA contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII V3888OEY5R - VERAPAMIL HYDROCHLORIDE
 

Verapamil inhibits the transmembrane influx of calcium ions into the heart and vascular smooth muscle cell. The myocardial oxygen demand is lowered directly as a result of the effect on the energy consuming metabolic processes of the myocardial cell and indirectly due to a reduction of the afterload. Due to its effect on coronary vascular smooth muscle, verapamil enhances myocardial blood flow, even in post‐stenotic areas, and relieves coronary spasms. These properties contribute to the anti‐ischaemic and antianginal efficacy of verapamil in all types of coronary artery disease.

 
Read more about Verapamil
2
UNII 1T0N3G9CRC - TRANDOLAPRIL
 

Trandolapril is a prodrug, which is rapidly, non-specifically hydrolysed to its potent, long-acting active metabolite, trandolaprilat (other metabolites are inactive) and acts as an orally-active angiotensin converting enzyme inhibitor (ACE inhibitor) without a sulphydryl group. In addition to inhibition of plasma ACE, trandolapril has been experimentally shown to inhibit tissue ACE (particularly vascular, cardial and adrenal). The clinical relevance of tissue ACE inhibition has not been established in humans.

 
Read more about Trandolapril

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 TARKA Film-coated tablet MPI, US: SPL/Old FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
C09BB10 Trandolapril and verapamil C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09B ACE inhibitors, combinations → C09BB ACE inhibitors and calcium channel blockers
Discover more medicines within C09BB10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 2857J, 9387C
DE Bundesinstitut für Arzneimittel und Medizinprodukte 01169936, 03359486, 04127714, 04167317, 04167323, 04167346, 05484474, 05491273, 06113372, 06492257, 09687406, 09946380, 12450932
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 29349-08-10, 5476-MEE-0920
EE Ravimiamet 1233290, 1233302, 1233313, 1233324, 1233335, 1233346, 1377389, 1377390, 1377402, 1377413, 1377424, 1377435, 1377660, 1377671, 1377682, 1377693, 1377705, 1377716
ES Centro de información online de medicamentos de la AEMPS 61369
FR Base de données publique des médicaments 60516982, 62404028, 64603331
HR Agencija za lijekove i medicinske proizvode HR-H-037957008, HR-H-738517235
LT Valstybinė vaistų kontrolės tarnyba 1005320, 1005353, 1024925, 1038602, 1038603, 1059888, 1059889, 1059890, 1059891
MX Comisión Federal para la Protección contra Riesgos Sanitarios 245M98
NL Z-Index G-Standaard, PRK 96644
PL Rejestru Produktów Leczniczych 100178278
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W68849001, W68850001, W68850002, W68850003, W68850004, W68850005, W68850006, W68850007, W68851001, W68851002, W68851003, W68851004, W68851005, W68851006, W68851007
TR İlaç ve Tıbbi Cihaz Kurumu 8699548092732, 8699548093050
US FDA, National Drug Code 0074-3287, 0074-3289, 0074-3290
ZA Health Products Regulatory Authority 31/7.1.3/0631, A39/7.1.3/0508, A39/7.1.3/0547

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.